Drug Delivery Systems

Jimi Sta. Maria is incubating GeneHarmonics Inc. to complete the ABC of converging technologies that will usher in major innovations for the future. A stands for the ATOM which is represented by the Quantum Dot technology being used for its diagnostics devices, B stands for a BIT which is the fundamental unit in the data platform being developed under BitHarmonics, and C stands for CELL which is the fundamental unit of concern in novel therapies and drug development.

The identification and isolation of biomarkers to be bio-conjugated with Quantum Dots to monitor effects of intervention for drug development will be a groundbreaking application. It’ll accelerate the process, reduce the cost and mitigate risks associated with clinical trials.

GeneHarmonics is being registered in the State of Delaware. GeneHarmonics will be structured as an affiliate company to NanoHarmonics, Inc. 15% to 20% of the initial set of issued stocks will be allocated for NanoHarmonics, Inc. while specific amounts will be issued to new partners who will be specialists in the drug delivery development space.

Jimi is currently in discussions with drug delivery system biotech companies from California who are excited to partner not only because of his access to technology that can monitor biomarkers but also because of the infrastructure in the US and Asia that can shorten the time towards commercialization.

On-going talk about partnerships on drug delivery systems and drug development are currently underway with dominant pharmaceutical companies in Asia. Hospitals who would participate in clinical trials are also underway. Strategic alliances that are in place include pathways towards, commercialization, monetization, access to grant money, and others.

We have the foundational technology to develop rapid and quantitative diagnostics tests for different biomarkers using Quantum Dots. The quantitative features as well as the accuracy levels of our tests make them ideal for immunity level detection, biomarker monitoring in drug development, infectious diseases management through population studies for predictive models, and  biomarkers trends monitoring for personal health.


We are developing a companion secured and encrypted data platform for our Quantum Dot diagnostics. Numerical data from test results will be organized and managed to allow people to monitor trends of biomarkers associated with their health concerns, anonymized positive or negative population data for infectious diseases management, and monitor biomarkers to accelerate drug development for pharmaceutical companies.


We are partnering with several companies who bring novel drug delivery systems that will benefit from our Quantum Dot diagnostics technology and our data platform to participate in population studies that we are spearheading to create predictive models for infectious diseases.  We are helping in the formulation of  new drugs with potential increases in the bioavailability of beneficial APIs while substantially reducing toxicity and side effects.